Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Preclinical data demonstrated that combining an anti–programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregory, Gareth P., Kumar, Shaji, Wang, Ding, Mahadevan, Daruka, Walker, Patricia, Wagner-Johnston, Nina, Escobar, Carolina, Bannerji, Rajat, Bhutani, Divaya, Chang, Julie, Hernandez-Ilizaliturri, Francisco J., Klein, Andreas, Pagel, John M., Rybka, Witold, Yee, Andrew J., Mohrbacher, Anne, Huang, Mo, Farooqui, Mohammed, Marinello, Patricia, Quach, Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864641/
https://www.ncbi.nlm.nih.gov/pubmed/34972202
http://dx.doi.org/10.1182/bloodadvances.2021005872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864641/
https://www.ncbi.nlm.nih.gov/pubmed/34972202
http://dx.doi.org/10.1182/bloodadvances.2021005872

Ejemplares similares